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Tumour cell invasion and metastatic spread to peripheral organs
have been found to proceed in three distinct stages: (1) the attach-
ment of tumour cells to the basement membrane via cell surface
receptors such as integrins and proteoglycans; (2) the degradation
of basement membrane components, which is mediated by locally
secreted enzymes; and (3) the migration of tumour cells into the
digested matrix (Kramer et al, 1986; Albini et al, 1987;
Aznavoorian et al, 1993). Mature and neoplastic lymphoid cells
circulate between blood and lymphoid organs by extravasation
through both the endothelium and the basement membrane around
capillaries, and then by migration along the extracellular matrix in
the perivascular space (Segat et al, 1994). Matrigel, which is
composed of basement membrane components including laminin,
collagen type IV, proteoglycans and several growth factors, has
been shown to promote the growth of leukaemic cells in xenograft
models (Cavallo et al, 1991; Sterling-Levis et al, 1993). We have
previously demonstrated the ability of Matrigel to promote tumour
formation and dissemination to peripheral organs in severe
combined immune deficient (SCID) mice using pre-B acute
lymphoblastic leukaemia (ALL) cells (Ishii et al, 1995). Matrigel
may provide a stromal-like support to leukaemic cells. The
interaction between leukaemic cells and the matrix proteins via
integrins or other cell surface receptors seems to be critical for
the growth and dissemination of leukaemia in vivo.
Laminin-1, the major component of basement membrane and
Matrigel, promotes cell adhesion, collagenase IV production, cell
motility, and tumour growth and metastasis (Martin and Timpl,
1987; Timpl, 1989; Beck et al, 1990). Several active sites on
laminin-1 have been identified using proteolytic fragments and
synthetic peptides (Yamada and Kleinman, 1992). The peptide
YIGSR (Tyr–Ile–Gly–Ser–Arg) comprised of residues 929–933
on the b1 chain has been found to inhibit tumour growth and
metastasis (Graf et al, 1987; Iwamoto et al, 1987; Fridman et al,
1990). Both polymerized and polyethylene glycol-conjugated
YIGSR peptides significantly enhanced the inhibitory effect of
tumour metastasis (Murata et al, 1989; Kawasaki et al, 1991). In
addition, when prepared as a multimeric peptide (Tam, 1988),
YIGSR was shown to be a potent inhibitor of melanoma cell
growth and metastasis (Nomizu et al, 1993). Multimeric YIGSR
peptide was also shown to promote the apoptosis of fibrosarcoma
cells, but not that of colon adenocarcinoma cells (Kim et al, 1994),
suggesting cell-type specificity.
In the present study, we examined whether the multimeric
YIGSR peptide has an anti-proliferative effect and/or prevents the
metastasis of human pre-B ALL cells (NALM6) in SCID mice.
We found that the multimeric YIGSR peptide significantly inhib-
ited tumour growth and leukaemic infiltration in various organs.
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Summary The YIGSR (Tyr–Ile–Gly–Ser–Arg) laminin b1 chain sequence has an inhibitory effect on tumour growth and the metastasis of
melanoma and fibrosarcoma cells. In the present study, we investigated whether the multimeric YIGSR peptide (Ac-Y16) has an anti-
proliferative effect and/or prevents the metastasis of human pre-B acute lymphoblastic leukaemia cells (NALM6) in severe combined immune
deficient (SCID) mice. In in vitro studies, Ac-Y16 significantly inhibited leukaemic cell colony formation and the invasion of NALM6 cells in a
Matrigel-based assay. The tumour growth and leukaemic infiltration in peripheral tissues were also analysed in SCID mice 9 weeks after
NALM6, Matrigel and Ac-Y16 were subcutaneously co-injected. The weight of the subcutaneous tumours was significantly suppressed by
Ac-Y16 in a dose-dependent manner. Flow cytometry analysis showed that the leukaemic infiltration was significantly inhibited in all organs
with 1.5–2.0 mg of Ac-Y16. Leukaemic infiltrations in the brain were inhibited with 0.5 mg of Ac-Y16, and those in brain and bone marrow
were also inhibited with 1.0 mg of Ac-Y16. With Ac-S16, a control-scrambled peptide, the only significant inhibition of the leukaemic infiltration
was observed in bone marrow at a much higher dose. These data suggest that the multimeric YIGSR peptide can inhibit the tumour growth
and metastasis of leukaemic cells and may be useful as a potential therapeutic reagent for leukaemic infiltrations.
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MATERIALS AND METHODS
Synthesis of peptides
The multimeric YIGSR peptide (Ac-Y16), (CH3CO–Tyr–Ile–
Gly–Ser–Arg–Gly)16–Lys8–Lys4–Lys2–Lys–Gly ((Ac-YIGSRG)16-
K8K4K2KG), was synthesized as described previously (Nomizu
et al, 1993). The peptide has 16 copies of the YIGSR sequence on
a branched lysine tree and has a molecular weight of approxi-
mately 10 000. A scrambled multimeric peptide (Ac-S16),
(Ac-GYSRIG)16K8K4K2KG, was also synthesized as a control. The
molecular weight of Ac-S16 is the same as that of AC-Y16. These
peptides were purified by reverse-phase high-performance liquid
chromatography. In this study, different amounts of Ac-Y16 (from
0.5 mg to 2.0 mg) were tested to examine the dose efficacy of the
peptide. As a control peptide, 1.5 mg of Ac-S16 was also used
with leukaemic cells and Matrigel.
Colony assay
The effect of Ac-Y16 on the colony formation of leukaemic cells
was examined. NALM6 cells (1 ´ 106) were mixed with Matrigel
and 0.5–2.0 mg of Ac-Y16 or 1.5 mg of Ac-S16, and 1 ´ 104 cells
were incubated in the presence of methylcellulose as previously
reported (Nakahata and Ogawa, 1982; Imai et al, 1991). Briefly,
1 ml of culture mixture containing leukaemic cells, Matrigel,
Ac-Y16 or Ac-S16, a-MEM (ICN Biomedicals, Costa Mesa, CA,
USA), 0.9% methylcellulose (Shin-etsu Chemical Co, Tokyo,
Japan), 25% fetal bovine serum (FBS), 1% deionized bovine
serum albumin (Sigma Chemical Co., St Louis, MO, USA), and
5 ´ 10–5 mol l–1 2-mercaptoethanol (Sigma), was plated in a 35 mm
Lux standard non-tissue culture dish (Nunc, Inc., Naperville,
IL, USA) and incubated for 7 days at 37°C in a humidified atmos-
phere flushed with 5% carbon dioxide, 5% oxygen and 90% N2.
The number of leukaemic colonies (defined as > 40 cells) was
counted using an inverted microscope. All experiments were
performed using quadruplicate samples.
Invasion assay
The invasion of leukaemic cells and its inhibition by Ac-Y16 or
Ac-S16 were analysed in the Matrigel-based assay according to
the previous methods (Janiak et al, 1994; Matsuzaki et al, 1996).
The Matrigel invasion chamber containing an 8-micron pore size
membrane coated with Matrigel was used for the study (Becton
Dickinson, Bedford, MA, USA). Lower compartments of the
chambers were filled with 500 ml of RPMI-1640 medium. The
leukaemic cells (1 ´ 106) were mixed with 0.5–1.5 mg of Ac-Y16
or 1.5 mg of Ac-S16 in the final volume of 1 ml. Then 200 ml of
the cells were placed in the upper compartment (0.2 ´ 106 cells per
chamber). After incubation for 4 h at 37°C, the number of cells
that had migrated into the lower compartment of each chamber
was counted to determine the percentage of invasion. All experi-
ments were performed using three chambers for each sample.
Engraftment of pre-B leukaemic cells in SCID mice
NALM6, a human pre-B ALL cell line (Uckun et al, 1992), was
maintained in RPMI-1640 medium with 10% FBS (Gibco, Grand
Island, NY, USA). The SCID mice were bred and maintained in
defined flora colonies (Faculty of Medicine, Kyushu University,
Fukuoka, Japan). The engraftment of NALM6 cells in SCID mice
was performed as described previously (Ishii et al, 1995). Briefly,
NALM6 cells (2 ´ 106) and 2 mg of Matrigel (Becton Dickinson)
were co-injected subcutaneously (s.c.) with 0.5–2.0 mg of Ac-Y16
or 1.5 mg of Ac-S16 in 8–10-week-old SCID mice. After 9 weeks,
the mice were sacrificed and the tumour weights in mice with or
without either Ac-Y16 or As-S16 were measured. The s.c. tumour,
spleen, liver, lung, kidney, brain and bone marrow (BM) in each
mouse were excised and minced with a 40-mesh screen. The cell
suspensions of each organ were washed several times with
medium and then subjected to flow cytometry. The number of
mice analysed in the study was 5–8 in each group. Total RNA was
extracted from these tissues for analysis by the reverse transcrip-
tase polymerase chain reaction (RT-PCR) method.
Flow cytometry
CD10- and CD19-positive human cells in each organ were
analysed with monoclonal antibodies by two-colour direct
immunofluorescence to measure infiltration by leukaemic cells.
Cell suspensions from tumours, spleen, liver, lung, kidney and
brain were prepared by a tissue grinder. A cell suspension from
BM was also prepared by gentle pipetting. Aggregated cells or
residual tissues were removed by brief sedimentation. For erythro-
cyte lysis, each sample was diluted with NH4Cl lysis buffer and
after gentle mixing kept at room temperature for 3–5 min.
Aliquots of a cell suspension (1 ´ 106 cells) from the primary
tumours, spleen, liver, lung, kidney, brain and BM were incubated
with 10 ml of fluorscein isothiocyanate (FITC)-conjugated OKB
CALLA specific for CD10 (Ortho Diagnostic Systems, Raritan,
NJ, USA) and 20 ml of PE-conjugated HD37 specific for CD19
(Dako, Glostrup, Denmark) to identify human leukaemic cells.
Samples were then mixed gently, incubated at 4°C for 30 min and
washed twice in phosphate-buffered saline (PBS). For the flow
cytometric analysis, 2 ´ 104 cells were analysed on a FACScan
(Becton Dickinson, Mountain View, CA, USA). Human and
murine BM or peripheral blood cells were used for the gating of
mononuclear cells. In each experiment, cells from non-trans-
planted mice were stained with the same antibodies, as a negative
control. An isotype control antibody was also used. The percent
infiltration of leukaemic cells was defined as the ratio of the
number of CD10+CD19+-positive cells to that of all mononuclear
cells in each organ.
RT-PCR
Total RNA was extracted from tumour and organ homogenates
(Ishii et al, 1995). cDNA was prepared by RT at 37°C for 60 min
in a 50 ml mixture containing 5 mg RNA, 1 mg oligo-dT and 100
units of MMLV reverse transcriptase (Life Technology, Rockville,
MD, USA). The integrity of RNA and cDNA was confirmed by
the generation of a b-actin PCR product (228 bp) with primers
which hybridize with both human and murine b-actin (actin-MH);
5¢-CTACAATGAGCTGCGTGTGG-3¢ and 5¢-TAGATGGGCAC-
AGTGTGGGT-3¢ (Nakajima-Iijima et al, 1985). Primers specific
for human b-actin (actin-H) were also prepared to detect human
leukaemic cells in mouse organs. These primers were
5¢-GGCCACGGCTGCTTCCAG-3¢ and 5¢-CATTGTGCTGGGT-
GCCAGG-3¢ (Nakajima-Iijima et al, 1985). The expected size of
the PCR product was 295 bp. The PCR was performed with cDNA
in a total volume of 50 ml, containing 1 ´ PCR buffer, 200 mM1900 N Yoshida et al
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dNTPs, 0.5 mg each of the 5¢ and 3¢ primers and 2.5 units of Taq
polymerase (Perkin-Elmer, Norwalk, CT, USA). The amplification
profile involved 30 cycles of denaturation at 94°C for 30 s, primer
annealing at 53°C for 30 s and extension at 72°C for 1 min. The
PCR products were resolved by electrophoresis in 2% agarose
gels, stained with ethidium bromide and photographed. The
reproducibility of the PCR analysis was confirmed by several
independent experiments.
Apoptosis assays
NALM6 cells (4 ´ 105 ml–1) were co-incubated with 2–50 mg of
Ac-Y16 or Ac-S16 for 12 h at 37°C. After staining leukaemic cells
with 10 ml of FITC-conjugated annexin V and 5 ml of propidium
iodide (MEBCYTO-Apoptosis Kit, MBL, Japan) for 15 min, the
number of apoptotic cells was measured by flow cytometry (van
Engeland et al, 1998). We also measured the mitotic index of
leukaemic cells and the number of apoptotic cells in the s.c.
tumours by histological examination and/or TUNEL assays
(ApoptaqPlus, Oncor, Gaithersburg, MD, USA).
Statistical analysis
Differences in the colony formation and invasion of leukaemic
cells in vitro between the test concentration groups were compared
by the Kruskal–Wallis test. The tumour weight and the infiltration
of leukaemic cells in mice with or without Ac-Y16 or Ac-S16
were also compared by the Kruskal–Wallis test. A multiple
comparison test was performed using the method of Bonferroni
adjustment when the the Kruskal–Wallis test showed P < 0.05
(Alt, 1982).
RESULTS
Effect of Ac-Y16 on the colony formation and invasion
of leukaemic cells
We examined the effect of Ac-Y16 on the colony formation of
leukaemic cells in vitro. NALM6 cells were incubated with
Matrigel and 0.5–2.0 mg of Ac-Y16 or 1.5 mg of Ac-S16, and the
number of leukaemic colonies was measured after 7 days of
incubation. As shown in Figure 1A, the number of colonies was
decreased with increasing amounts of Ac-Y16. A significant
difference was observed between test concentration groups
(P < 0.01). Ac-S16, the control-scrambled peptide, did not inhibit
the colony formation of NALM6 cells. Thus, the Ac-Y16 peptide
inhibited leukaemic cell growth in vitro.
The in vitro effect of Ac-Y16 on the invasion of leukaemic cells
was also examined (Figure 1B). Approximately 1.25–1.50% of the
leukaemic cells migrated through a Matrigel-coated membrane.
With increasing amounts of Ac-Y16, the percentage of leukaemic
cells that migrated into lower compartment was significantly
decreased (P < 0.05). Ac-S16 showed little effect on the cell
migration. These data suggest that laminin plays an important role
in leukaemic cell invasion in vitro.
To examine whether Ac-Y16 induces apoptosis of leukaemic
cells, NALM6 cells were co-cultured with 2–50 mg of Ac-Y16 or
Ac-S16 and the number of apoptotic cells was measured by flow
cytometry. The percentage of apoptotic cells was less than 3% in
control leukemic cells, whereas in cells treated with Ac-Y16
10.8% at 2 mg ml–1, 10.3% at 10 mg ml–1 and 33.1% at 50 mg ml–1
of Ac-Y16 were apoptotic after 12 h of treatment. Control Ac-S16
showed less apoptosis than Ac-Y16, i.e. 8.8% at 2 mg ml–1, 8.1% at
10 mg ml–1 and 13.5% at 50 mg ml–1.
Effects of the multimeric YIGSR (Ac-Y16) peptide on
tumour growth and the dissemination of leukaemic
cells in SCID mice
Human pre-B leukaemia NALM6 cells (2 ´ 106) and Matrigel
(2 mg) were injected s.c. in SCID mice with or without the multi-
meric YIGSR peptide (Ac-Y16). As a control, Ac-S16 was also
injected with Matrigel and NALM6 cells. After 9 weeks, the
growth of the primary tumour and the infiltration of leukaemic
cells into the spleen, liver, lung, kidney, brain and BM were
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Figure 1 Inhibitory effect of Ac-Y16 or Ac-S16 on the colony formation (A)
and the invasive potential (B) of NALM6 cells. Significant inhibition by
Ac-Y16 was observed in colony formation (P < 0.01) and invasiveness
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analysed. The weight of the s.c. tumours differed significantly in
the mice with or without Ac-Y16 or Ac-S16 (P = 0.0004) (Figure
2). No tumour formation was observed in mice when 1.5 or 2.0 mg
of Ac-Y16 was coinjected. One milligram of Ac-Y16 significantly
inhibited tumour growth (P < 0.01) by more than 90%. In contrast,
when 1.5 mg of Ac-S16 were co-injected with leukaemic cells, a
lesser inhibitory effect on tumour growth was observed. However,
these differences were not significant (Figure 2). To examine
whether the inhibition by Ac-Y16 of tumour growth is due to the
inhibition of cell proliferation, to cell death by apoptosis, or both,
we measured the mitotic index of leukaemic cells and the number
of apoptotic cells of the s.c. tumours. The mitotic index and the
number of apoptotic cells were not significantly different in the
s.c. tumours with and without Ac-Y16 or Ac-S16 (data not
shown). These findings were confirmed by the staining with MIB-
1 monoclonal antibodies to detect mitotic cells.
The infiltration of leukaemic cells in peripheral organs was
assessed in a flow cytometry analysis. The flow cytometric
profiles of representative samples obtained from untreated control
mice and those with leukaemic cells and Matrigel are given in
Figure 3. All of the organs from untreated mice showed no or very
low reactivity with both the CD10 and CD19 antibodies, whereas
high numbers of CD10+CD19+ cells were detected in organs from
mice with leukaemic cells and Matrigel. Figure 4 shows the per
cent infiltration of leukaemic cells in all organs from six different
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Figure 2 Inhibition of tumour formation by Ac-Y16 and Ac-S16. Nine weeks
after the injection of NALM6 cells with Matrigel and 0.5–2.0 mg of Ac-Y16 or
1.5 mg of Ac-S16, the tumour growth was analysed. The tumours decreased
with the dose of Ac-Y16; a significant difference in the tumour weight was
observed between mice with Matrigel alone and those with 1.0–2.0 mg of
Ac-Y16. Each horizontal bar indicates the mean value of the samples
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Figure 3 The reactivity with CD10- and CD19-specific antibodies in organs from control untreated mice, mice treated with leukaemic cells and Matrigel, or
those treated with leukaemic cells and Matrigel/Ac-Y16. No or very low numbers of CD10+CD19+ cells were observed in the control mice, whereas high
numbers of CD10+CD19+ cells were detected in the mice with Matrigel. The infiltration of CD10+CD19+ cells was suppressed by 1.5 mg of Ac-Y16
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Figure 4 Infiltration of leukaemic cells in peripheral organs. The leukaemic infiltration, defined as the per cent of CD10+CD19+ human cells in each organ, was
measured by flow cytometry and plotted. Each horizontal bar shows the mean of the per cent infiltration of leukaemic cells in mice. Lane 1, mice with Matrigel
(n = 8); lane 2, mice with Matrigel and 0.5 mg Ac-Y16 (n = 8); lane 3, mice with Matrigel and 1.0 mg Ac-Y16 (n = 8); lane 4, mice with Matrigel and 1.5 mg Ac-
Y16 (n = 8); lane 5, mice with Matrigel and 2.0 mg AC-Y16 (n = 5); lane 6, mice with Matrigel and 1.5 mg Ac-S16 (n = 5)Inhibition of leukaemic cell growth and metastasis by laminin peptide YIGSR 1903
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groups of mice. High levels of leukaemic infiltration were
observed in the spleen, liver, lung, kidney, brain and BM of all
mice with Matrigel alone. The infiltration of leukaemic cells in the
mice with and without Ac-Y16 or Ac-S16 was significantly
different in all organs: P = 0.0075 in spleen, P = 0.0001 in liver,
P = 0.0001 in lung, P = 0.0018 in kidney, P < 0.0001 in brain and
P < 0.0001 in BM. Two mg of Ac-Y16 completely suppressed the
infiltration of leukaemic cells in all organs. At 1.5 mg of Ac-Y16,
the leukaemic infiltration was significantly inhibited in the spleen
(P < 0.05) and other organs (P < 0.01), which is also shown in
Figure 3. Of all the organs examined, the brain was the most sensi-
tive to the presence of the test peptide. Only a low infiltration of
leukaemic cells was observed in the brain of mice treated with 
Ac-Y16 at 0.5 mg or at 1.0 mg. In contrast, with 1.5 mg of
Ac-S16, a significant inhibition of leukaemic infiltration was
observed only in BM (P < 0.01).
The dissemination of leukaemia cells was also assessed by the
RT-PCR analysis of human b-actin mRNA expression in the
spleen, brain and BM (Figure 5). Human b-actin mRNA was
detected in the spleen, brain and BM of mice treated with Matrigel
alone. In the mice treated with 1.0 mg of Ac-Y16, the expression
of human b-actin mRNA was observed in only the spleen and BM;
the brain showed undetectable levels of human b-actin mRNA.
Mice treated with 1.5 mg of Ac-Y16 showed undetectable mRNA
of b-actin in all organs. In contrast, the human b-actin mRNA was
detected in mice with 1.5 mg of Ac-S16. The BM in mice treated
with Ac-S16, which showed only a small infiltration of leukaemic
cells by flow cytometry, also expressed human b-actin by RT-
PCR. Thus, Ac-Y16 inhibited the tumour growth and dissemina-
tion of leukaemic cells into peripheral organs in a dose-dependent
manner.
DISCUSSION
The Tyr–Ile–Gly–Ser–Arg (YIGSR) sequence derived from the
laminin b1 chain has been shown to inhibit tumour growth and
metastasis (Graf et al, 1987; Iwamoto et al, 1987; Saiki et al, 1989;
Fridman et al, 1990). It was reported that the multimeric YIGSR
polypeptide greatly enhanced the inhibition of tumour growth and
metastasis (Nomizu et al, 1993). Although the mechanisms of this
effect of YIGSR are still not clear, recent results have suggested
that apoptosis may play a role in the anti-metastatic and anti-
tumour effects associated with multimeric YIGSR peptide in HT-
1080 human fibrosarcoma cells (Kim et al, 1994). However, cell
type-specific apoptosis by YIGSR has not been demonstrated
(Kim et al, 1994). It was also reported that YIGSR reduces angio-
genesis (Sakamoto et al, 1991; Iwamoto et al, 1996).
The interaction between Matrigel and leukaemic cells can also
facilitate a proliferative response (Sterling-Levis et al, 1993; Ishii
et al, 1995; Yan et al, 1996). As shown in a previous report (Blase
et al, 1996), NALM6 expressed high levels of VLA-a3, -a4, -a5
and -a6, and VLA-b1. VLA-a6, which is usually expressed on
pre-B leukaemic cells, interacts with laminin (Hynes, 1992). In
fact, NALM6 cells mainly adhere to laminin, and this binding is
significantly reduced by the b1 and a6 monoclonal antibodies
(Blase et al, 1996). We also found that Ac-Y16 has similar activity
for NALM6 cell attachment (data not shown). However, the
binding site of laminin-1 for VLA-a3 and a6 integrins is the
C-terminal portion (Hall et al, 1990; Tomaselli et al, 1990;
Sonnenberg et al, 1991), while YIGSR has been shown to recog-
nize 36-kDa, 38-kDa and 67-kDa cell surface proteins (Graf et al,
1987; Clement et al, 1990) and a4b1 integrin (Maeda et al, 1994).
Taken together, these findings indicate that YIGSR may inhibit
tumour formation and leukaemic infiltration by competing with
laminin for these laminin receptors and/or integrins on leukaemic
cells, thus blocking the binding of the cells to basement membrane
(Iwamoto et al, 1987).
In our study, the growth and dissemination of leukaemic cells
were inhibited by the multimeric YIGSR peptide in vivo and in
vitro. The precise mechanism of the drug-provoked tumour inhibi-
tion is unclear. Although the direct toxicity of YIGSR peptide for
leukaemic cells cannot be completely ruled out, Ac-Y16 reduced
tumour growth at 0.5–1.0 mg in vitro and selectively inhibited the
dissemination of leukaemic cells in vivo. Previous data also
suggested that Ac-Y16 is not cytotoxic in vivo (Iwamoto et al,
1996). In the present study, the high dose (1.5–2.0 mg) of Ac-Y16
clearly inhibited the tumour formation and leukaemic infiltration in
all peripheral organs, compared with the same dose of Ac-S16, a
scrambled multimeric peptide, which showed only a weak
inhibitory effect on leukaemic infiltration. Apoptosis of NALM6
cells were induced by Ac-Y16 in cultures, whereas the number of
apoptotic cells in the s.c. tumours was not increased by Ac-Y16.
Although this discrepancy is not clear, it is possible that the sensi-
tivity of the apoptosis assays may be different between cell cultures
and in vivo. Another possibility is that Ac-Y16-mediated apoptosis
may occur in much earlier stages after the inoculation of NALM6
cells with Ac-Y16 in SCID mice. Our apoptosis assays were
performed at 12 h after the incubation and at this late stage apoptotic
cells may not be present and could not be detected. Alternatively,
Ac-Y16 may be more potent in inhibiting tumour cell proliferation
or inducing necrosis of tumour cells than apoptosis in vivo.
In the previous study, the proliferation of HT-1080 cells was
markedly decreased by Ac-Y16 at 60–100 mg ml–1, while only a
small effect was observed at 30 mg ml–1 (Kim et al, 1994).
Proliferation of SW480 cells was reduced at 100 mg ml–1, but had
no effect at 30 mg  ml–1 (Kim et al, 1994).  In our study, the colony
formation of leukaemic cells was partially suppressed by Ac-Y16
at 0.5–2.0 mg per 106 cells (5–20 mg ml–1). Although assays used
for these two studies are different, their data suggest that the
inhibitory activity of Ac-Y16 varies with different cell types.
Leukaemic cells usually spread from bone marrow or the
tumour burden to peripheral organs as overt leukaemia. In order to
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Figure 5 Infiltration of leukaemic cells in the mouse spleen, brain and BM
assessed by RT-PCR. Human b-actin mRNA (actin-H) was detected in the
spleen, brain and BM of mice with Matrigel alone (lane 1), and with 1.5 mg of
Ac-S16 (lane 4). In mice treated with Ac-Y16, only the spleen and BM
expressed human b-actin at 1.0 mg (lane 2), whereas there was no
expression of human b-actin in these organs at 1.5 mg (lane 3). Actin-MH
was used as an internal control. PC, NALM6 cells as a positive controldisseminate, leukaemic cells enter the circulatory system by
crossing the endothelium and the basement membrane. The multi-
meric YIGSR peptide may inhibit the spreading of leukaemic cells
to the vascular endothelium, by blocking leukaemic cell binding to
laminin. Only one leukaemic cell line was used in the present
study; further analyses is necessary to examine the inhibitory
activity of Ac-Y16 for primary leukaemic cells from patients.
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